Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 14/20 | 0.62 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497214 | 0.90 | ICMT (0.66) | ICMTSERPINE1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12572685 | 0.80 | ICMT (0.70) | ICMTSERPINE1ALDH1A1LMNA | |
| SCHEMBL4941452 | 0.80 | ICMT (0.70) | ICMTSERPINE1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27556132 | 0.79 | LMNA (0.56) | CYP1A2CYP2C9CYP2C19HTTNPSR1 | |
| SCHEMBL3861443 | 0.78 | ICMT (0.67) | ICMTSERPINE1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5572599 | 0.72 | SERPINE1 (0.60) | ICMTSERPINE1ALDH1A1LMNA | |
| SCHEMBL12572676 | 0.70 | ICMT (0.74) | ICMT | |
| SCHEMBL27740513 | 0.69 | LMNA (0.54) | CYP1A2CYP2C9CYP2C19HTTNPSR1 | |
| SCHEMBL12572673 | 0.68 | ICMT (0.73) | ICMTSERPINE1 | |
| SCHEMBL4940403 | 0.67 | ICMT (0.53) | ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2008097897-A9 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1(PAI-1) | WYETH CORP (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008097953-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-08-14 | — | — | WO | claimed |
| WO-2008097897-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1(PAI-1) | WYETH (US) | 2008-08-14 | — | — | WO | claimed |
| US-20080188540-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-08-07 | — | — | US | claimed |
| US-20080188543-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2008-08-07 | — | — | US | claimed |
| US-7368471-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-05-06 | — | — | US | claimed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| EP-1397130-B1 | SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | ICMT 4550/4885SERPINE1 1/4885CYP1A2 4381/4885 |
| US-20080188540-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, TFPI, MMP1 | ICMT 761/4885SERPINE1 1/4885CYP1A2 349/4885 |
| US-20080188543-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED INDOLE ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | SERPINE1, MMP1, TFPI | ICMT 730/4885SERPINE1 1/4885CYP1A2 344/4885 |
| US-20060167059-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F12 | ICMT 2376/4885SERPINE1 1/4885CYP1A2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.